20161122_mc2-portrait-04

Latest News:

MC2 Therapeutics A/S announces completion of recruitment in Phase 2 study in moderate-to-severe dry eye disease with MC2-03

POSTED: November 9, 2017

  • Completion of patient recruitment meeting randomization target of 264 patients
  • Topline results are expected in 2018

 Copenhagen, November 9th, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today ...

READ FULL ARTICLE >

MC2 Therapeutics A/S announces first patient dosed in pivotal US Phase 3 trial in psoriasis vulgaris

POSTED: October 9, 2017

  • First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in US
  • Topline results are expected in Q3 2018

Copenhagen, October 9th, 2017 – MC2 ...

READ FULL ARTICLE >

MC2 Therapeutics A/S appoints Anders D. Hove and Paul L. Berns to the Board of Directors

POSTED: August 1, 2017

Copenhagen, August, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, has appointed Dr. Anders D. Hove and Mr. Paul L. Berns to serve on the Board.

“On ...

READ FULL ARTICLE >

MC2 Therapeutics to present data at the 2017 ARVO Annual Meeting highlighting the therapeutic potential of PAD® Techno.

POSTED: May 1, 2017

Copenhagen, February 24th, 2017 – MC2 Therapeutics today announced that two abstracts were accepted for poster presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting ...

READ FULL ARTICLE >

Upcoming Events:

November 9th, 2017

OIS@AAO – Ophthalmology Innovation Summit

READ MORE >

November 15th – 16th, 2017

Jefferies 2017 London Healthcare Conference

READ MORE >

January 8th – 11th, 2017

J.P. Morgan 36th Annual Healthcare Conference 2018 (San Francisco)

READ MORE >

© mc2 therapeautics 2016